Associate
Elliott LaParne focuses on pharmaceutical patent litigation, with an emphasis on Abbreviated New Drug Application (ANDA) litigation.
Elliott applies his extensive research experience to successfully navigate complex pharmaceutical patent cases, combining his scientific background with his formidable litigation skills. As an undergrad, he enhanced his scientific knowledge by conducting Ph.D.-level research on the effects of nicotine on nicotinic acetylcholine receptors in human embryonic stem cells (hESCs) at the University of Pittsburgh School of Medicine. In law school, he authored a regional winning brief in the Saul Lefkowitz Moot Court Competition and demonstrated matching oral advocacy skills that enabled him to place at the national level.
Federal Circuit IP Blog
Recoup Your Investment and More – Your Equitable Intervening Rights Are Safe Recoup Your Investment and More – Your Equitable Intervening Rights Are Safe
February 24, 2021
Federal Circuit IP Blog
Sanctions and Standing Issues SPROUT from Appeal of Board Decision Sanctions and Standing Issues SPROUT from Appeal of Board Decision
October 29, 2020
Press Release
46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll 46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll
June 3, 2022
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.